Vera Therapeutics (VERA) Other Accumulated Expenses (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Other Accumulated Expenses data on file, last reported at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 148.53% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (up 148.53% YoY), and the FY2025 full-year result was $1.9 million, up 9.3% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $3.5 million, up from $1.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.7 million in Q3 2025 and bottomed at $174000.0 in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $820000.0 (2024), against an average of $1.2 million.
• The widest annual swing landed in 2022, when Other Accumulated Expenses plunged 73.87%; it then soared 217.35% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $295000.0 in 2022, then jumped by 90.85% to $563000.0 in 2023, then surged by 211.37% to $1.8 million in 2024, then increased by 9.3% to $1.9 million in 2025, then surged by 80.95% to $3.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $3.5 million (Q1 2026), $1.9 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.

Peer Comparison